A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate
- PMID: 2144207
- DOI: 10.1002/cncr.1990.66.s5.1058
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate
Abstract
In a multicenter Phase III trial 264 patients with advanced prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex supplemented by flutamide. Presently, median follow-up time is 30 months. A small difference in objective response was recorded in favor of the combination therapy, whereas no statistically significant difference was found in subjective response to therapy, time to progression, and overall survival. Adverse effects were more commonly encountered in the pharmacologically treated patients. It is concluded that the combination of zoladex plus flutamide is not clinically superior to orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Similar articles
-
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).Eur Urol. 1990;18 Suppl 3:41-4. doi: 10.1159/000463979. Eur Urol. 1990. PMID: 2151275 Clinical Trial.
-
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.Cancer. 1990 Sep 1;66(5 Suppl):1045-57. doi: 10.1002/cncr.1990.66.s5.1045. Cancer. 1990. PMID: 2144206 Clinical Trial.
-
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.Cancer. 1990 Sep 1;66(5 Suppl):1067-73. doi: 10.1002/cncr.1990.66.s5.1067. Cancer. 1990. PMID: 2144208 Clinical Trial.
-
Southwest Oncology Group strategies in prostatic carcinoma.Semin Surg Oncol. 1995 Jan-Feb;11(1):60-4. doi: 10.1002/ssu.2980110109. Semin Surg Oncol. 1995. PMID: 7754277 Review.
-
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].Urologe A. 1995 Sep;34(5):382-8. Urologe A. 1995. PMID: 7483154 Review. German.
Cited by
-
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.Curr Oncol. 2006 Jun;13(3):81-93. doi: 10.3747/co.v13i3.85. Curr Oncol. 2006. PMID: 17576447 Free PMC article.
-
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.Drugs. 1991 Feb;41(2):254-88. doi: 10.2165/00003495-199141020-00008. Drugs. 1991. PMID: 1709853 Review.
-
Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.Drugs Aging. 1991 Mar;1(2):104-15. doi: 10.2165/00002512-199101020-00003. Drugs Aging. 1991. PMID: 1794008 Review.
-
Maximal androgen blockade for advanced prostate cancer.Cochrane Database Syst Rev. 2000;1999(2):CD001526. doi: 10.1002/14651858.CD001526. Cochrane Database Syst Rev. 2000. PMID: 10796804 Free PMC article.
-
Drug therapy of prostatic cancer.Drugs Aging. 1991 Sep-Oct;1(5):353-63. doi: 10.2165/00002512-199101050-00003. Drugs Aging. 1991. PMID: 1838950 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical